Tweets
Year 2 f/u on PsA, axSpA, or RA using CT-P13, an infliximab (IFX) biosimilar. Pts either naive to IFX or switched from IFX:
💠IFX-naive: improved disease activity
💠IFX-switched: maintained stable disease
💠No new safety concerns
https://t.co/VGBicnq15w
#ACR21 Abst#0817 @RheumNow
Pedro Castillo @_Castillo_Pedro ( View Tweet )
4 years 8 months ago
Small but important study of LN Class III, IV, and/or V with 6/18 pts considered complete responders by UProt (<500mg/g) continued to⬇️in renal fxn over 5 yrs. Bottom line: even dramatic ⬇️UProt does not tell the whole story.
https://t.co/51x4DlXkJC
#ACR21 Abst#1284 @RheumNow
Pedro Castillo @_Castillo_Pedro ( View Tweet )
4 years 8 months ago
Infxn risk of 1st year on rituximab for mod to severe SLE vs standard-of-care
🔹Most common SoC Rx: MMF, Aza, and/or cyclophosphamide
🔹🚫significant diff
🔹RTX pts = ⬆️dz duration, ⬆️# of prior meds, ⬇️maintenance steroid dose
https://t.co/AYQFXqlubl
#ACR21 Abst1288 @RheumNow
Pedro Castillo @_Castillo_Pedro ( View Tweet )
4 years 8 months ago
SLE: Belimumab + standard rx significantly⬇️risk of severe flares vs placebo.
Greatest in those with:
🔹+dsDNA
🔹low C3 or C4
🔹SLICC/ACR Damage index of 0 (argument for early treatment!)
https://t.co/UcGXEklqwJ
#ACR21 Abst#1295
@RheumNow
Pedro Castillo @_Castillo_Pedro ( View Tweet )
4 years 8 months ago
Dr. Eric Ruderman gives his perspective on PsA data presented during the plenary session on Saturday at the #ACR21 annual meeting.
https://t.co/r9FgBO6VT7 https://t.co/JbV519XQoG
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Important differences between vascular pathologies seen in #COVID19 and DIC by Dr. D McGonagle
👉Fibrinogen - normal/sl. ⬆ in PIC-assoc'd COVID19 vs. ⬇ in DIC sec to MAS
@RheumNow #ACR21 #MedTwitter
📌https://t.co/DdmAhVIR51 https://t.co/Xw8LKaKcFd
Links:
sheila @RHEUMarampa ( View Tweet )
4 years 8 months ago
Dr. D.McGonagle on the patterns of dse ➡true #vasculitis vs. vasculitis mimics seen in skin of #COVID19 pts in this very informative slide
🔴Mild/no lung dse: vasc cuffing,⬆type1 IFN
🔴Severe dse: vasc occlusion,⬇type1 IFN
@RheumNow #ACR21 #MedTwitter
https://t.co/Y5S2k7LO1p https://t.co/puBJm4Kd8H
Links:
sheila @RHEUMarampa ( View Tweet )
4 years 8 months ago
Interesting twist to an #ACR21 keynote lecture: Q&A!👏👏@DoctorYasmin
She even eloquently explained the etymology of crisis-the point in a pt's illness where they might rapidly deteriorate or recover, an inflection point (so relevant now) 👉to a new BETTER normal
@RheumNow https://t.co/UMKIC1tNos
sheila @RHEUMarampa ( View Tweet )
4 years 8 months ago
#ACR21 #YearinReview
Avacopan: The game changer for ANCA #vasculitis?🧐
🔅Remission at wk 26: Avacopan non-inferior to Pred (72.3% vs. 70.1%, p<0.001)
🔅Sustained remission at wk 56: Avacopan non-inferior to Pred (65.7% vs. 54.9%, p<0.001)
@RheumNow
https://t.co/CpPYVvRoMR https://t.co/QnsZIUQ0uu
Links:
sheila @RHEUMarampa ( View Tweet )
4 years 8 months ago
The AURORA 1 trial provided positive results for #lupus nephritis 👉rapid control of proteinuria w/o major side effects.
@RheumNow #ACR21 #YearinReview https://t.co/BWWZJtMPK0
sheila @RHEUMarampa ( View Tweet )
4 years 8 months ago
To cut back or continue? 🤔
The ARCTIC REWIND trial showed that RA pts in remission given half dose csDMARDs had ⬆ flares in 12 mos vs. stable dose csDMARD grp.
@RheumNow #ACR21 #YearinReview https://t.co/MXyD0epVcn
sheila @RHEUMarampa ( View Tweet )
4 years 8 months ago
Excited for the first full day of #ACR21, reporting for @RheumNow!
Esp looking forward to:
⭐Posters: #Epidemiology, #PublicHealth, #COVID19, #SpA, #RheumatoidArthritis, #PatientOutcomes
⭐Plenary session
⭐Scientific sessions covering #axSpA, #PsA and more
Mrinalini Dey @DrMiniDey ( View Tweet )
4 years 8 months ago
